Fact Source: Financial Supervisory Service DART / 2026-03-20
Disclosure Type: Results of Annual General Meeting of Shareholders
💡 3-Second Summary
Samsung Biologics held its 15th Annual General Meeting (AGM), officially approving financial statements featuring consolidated revenue of approx. KRW 4.56T and operating profit of KRW 2.07T. All proposed agendas, including amendments to the articles of incorporation and the re-election of Inside Directors John Rim and Kyun No, were approved as originally proposed.
📊 1. [Key Disclosure Content & Major Figures Summary]
- Approval of Financial Statements (15th Fiscal Period / Unit: KRW Millions):
- Consolidated: Total Assets 11,060,742, Total Liabilities 3,609,631, Total Equity 7,451,111, Revenue 4,556,972, Operating Profit 2,069,221, Net Income 1,784,352 (Earnings Per Share: KRW 24,091)
- Separate: Total Assets 11,023,969, Total Liabilities 3,608,520, Total Equity 7,415,449, Revenue 4,556,972, Operating Profit 2,068,093, Net Income 1,586,187 (Earnings Per Share: KRW 23,671)
- Audit Opinion: ‘Unqualified’ for both consolidated and separate financials (※ The name of the external auditor is not specified in this original disclosure text).
- Dividend Information: No cash, property, or stock dividends were declared or approved at this AGM (Not Applicable).
- Major Agenda Voting Outcomes:
- Agenda No. 1: Approval of the 15th Fiscal Period Financial Statements (Passed with 98.5% approval based on voting shares).
- Agenda No. 2: Amendments to the Articles of Incorporation (Sub-agenda 2-1 regarding exclusion of cumulative voting passed with 99.7% approval; Sub-agenda 2-2 reflecting Commercial Act revisions passed with 99.9% approval).
- Agenda No. 3: Election of Directors (Inside Director John Rim passed with 98.0% approval; Inside Director Kyun No passed with 97.6% approval, both re-elected for a 3-year term).
- Agenda No. 4: Election of Independent Director Kim Jung-yeon becoming an Audit Committee member (Passed with 97.8% approval for a 3-year term).
- Agenda No. 5: Approval of Director Remuneration Limit (Passed with 90.9% approval).
- Post-AGM Board Composition: 4 independent directors out of 7 total directors (57.14% ratio). The Audit Committee consists of 4 independent directors. The disclosure does not state specific reasons for the change in earnings performance.
📈 2. [Expert View: What This Disclosure Means for Investors]
The publication of these AGM results indicates that the 15th consolidated financial statements have received final statutory approval from shareholders. With the consolidated operating profit officially locked in at over KRW 2.07T as originally reported, uncertainties regarding the fiscal year’s financial closure and audit opinion may be considered diminished.
In terms of leadership stability, the approval of the 3-year terms for Inside Directors John Rim and Kyun No increases the likelihood that management continuity will be maintained. Furthermore, the amendments to the articles of incorporation, which update cumulative voting provisions and reflect recent changes to the Commercial Act, along with onboarding legal expert Kim Jung-yeon to the audit committee, reshape the structure of the board. This can be interpreted as an effort to improve the operational efficiency of corporate governance frameworks. No dividend payouts were finalized during this meeting, and investors should evaluate this filing based on the verified financial figures and the finalized alignment of the board of directors.
📝 Editor’s Comment (by K-STOCK Editor)
The 15th AGM disclosure of Samsung Biologics signals that the company’s fiscal performance and board appointments have now achieved final legal finalization. The financial statements, highlighted by a consolidated operating profit exceeding the KRW 2T milestone and a clean audit opinion, passed with an overwhelming 98.5% approval rating, underscoring fundamental stability. The simultaneous re-election of Inside Directors John Rim and Kyun No provides potential support for structural continuity within executive decision-making. Investors should observe how these corporate governance updates, including the newly structured audit committee and the updated articles of incorporation, affect future administrative efficiency, while closely following the ongoing steps of the finalized 7-member board.
📢 Disclaimer & Source Information
Source: This content has been newly structured and written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the individual investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
